Preclinical development of monoclonal antibodies for the treatment of AL cardiac amyloidosis

Amyloid cardiomyopathy is an under-recognized cause of heart failure and is caused by normal proteins in the bloodstream going bad (known as amyloid) and accumulating in the heart. This accumulation of amyloid in the heart tissue causes the wall of the heart to become rigid and ineffective at pumping blood to the rest of the body, causing heart failure. We are studying a form of amyloid cardiomyopathy called immunoglobulin light chain (AL) amyloidosis, caused by the accumulation of light chain proteins.